---
title: "BAOYE GROUP issues profit warning, expects mid-term net profit to decline by approximately 63%"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254124666.md"
description: "According to the Zhitong Finance APP, BAOYE GROUP announced that for the six months ending June 30, 2025, the company's owner profit is expected to decline by approximately 63% compared to the same period in 2024; the group's revenue is expected to decline by approximately 33% compared to the same period in 2024. The expected decline is mainly due to the industry downturn, which has led to a significant decrease in both revenue and profit from the group's construction and real estate development businesses"
datetime: "2025-08-22T08:43:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254124666.md)
  - [en](https://longbridge.com/en/news/254124666.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254124666.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/254124666.md) | [繁體中文](https://longbridge.com/zh-HK/news/254124666.md)


# BAOYE GROUP issues profit warning, expects mid-term net profit to decline by approximately 63%

According to the announcement from BAOYE GROUP (02355), for the six months ending June 30, 2025, the company's owner profit is expected to decline by approximately 63% compared to the same period in 2024; the group's revenue is expected to decline by approximately 33% compared to the same period in 2024. The expected decline is mainly due to the industry downturn, which has led to a significant decrease in both revenue and profit from the group's construction and real estate development businesses

### 相关股票

- [BAOYE GROUP (02355.HK)](https://longbridge.com/zh-CN/quote/02355.HK.md)

## 相关资讯与研究

- [CICC Sticks to Its Buy Rating for C&D International Investment Group Ltd. (1908)](https://longbridge.com/zh-CN/news/280899096.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-CN/news/281223382.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md)
- [CSC Financial Sticks to Their Buy Rating for Longfor Group Holdings (LNGPF)](https://longbridge.com/zh-CN/news/280898279.md)
- [Longfor Group Holdings (LNGPF) Gets a Buy from CICC](https://longbridge.com/zh-CN/news/280899756.md)